Pregnancy, HLA allogeneic challenge, and implications for AIDS etiology

Medical Hypotheses

Volumn 53, Issue 1, 1999, Pages 63-68

  Hoff, C ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; HLA ANTIGEN; IMMUNOGLOBULIN G;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CYTOTOXICITY; FETUS OUTCOME; GENETIC POLYMORPHISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; PLACENTA; PREGNANCY; PRIORITY JOURNAL;

EID: 0033166553     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1054/mehy.1997.0713     Document Type: Article

References (63)

1. Jacoby D. R., Olding L. B., Oldstone M. B. A. Immunologic regulation of fetal-maternal balance. Adv Immunol 1984; 35: 157-208.
2. Mogil R. J., Wegmann T. G. Maternal-fetal immunogenetics. In: Human Immunogenetics. New York: Marcel Dekker, 1989: 69-89.
3. Ahrons S. HLA-A antibodies: Influence on the human foetus. Tissue Antigens 1971; 1: 121-136.
4. Doughty R. W., Geselthorpe K. An initial investigation of lymphocyte antibody activity through pregnancy and in eluates prepared from placental material. Tissue Antigens 1974; 4: 291-298.
5. Jonker M., DeRooy-Doyer L. Possible mechanisms by which alloantisera inhibit in MLC test. Tissue Antigens 1980; 15: 1-10.
6. Jeannet M., Werner C., Ramirez E., Vassali P., Faulk W. P. Anti-HLA anti-human 'Ia-like' and MLC blocking activity of human placental IgG. Transplant Proc 1977; 9: 1417-1422.
7. Hogarth P. J. Immunological Aspects of Mammalian Reproduction. New York: Praeger Scientific, 1982.
8. Voisin G. A. Regulatory facilitation reaction and active tolerance: A non-Euclidean view of the immune reaction authenticated by immunology of reproduction. Immunol Letts 1987; 16: 283-290.
9. Wegmann T. G., Lin L. H., Guilbert L. J., Mossman T. R. Bidirectional cytokine interactions in the maternal-fetal relationship: Is successful pregnancy a TH2 phenomenon? Immunol Today 1993; 14: 353-356.
10. Mossman T. R., Saad S. The expanding universe of T-cell subsets: Th1, Th2, and more. Immunol Today 1996; 17: 138-146.
11. Hoff C., Peterson R. D. A. Associations between maternal and fetal serum levels of immune activation markers and fetal growth. Am J Hum Biol 1995; 7: 453-458.
12. Lencki S. G., Maciulla M. B., Eglinton G. S. Maternal and umbilical cord serum interleukin levels in preterm labor with clinical chorioamnionitis. Am J Obstet Gynecol 1994; 170: 1345-1351.
13. Tomkinson B. E., Brown M. C., Ip S. H., Carrabis S., Sullivan J. L. Soluble CD8 during T cell activation. J Immunol 1989; 142: 2230-2236.
14. Weinberg E. D. Pregnancy-associated depression of cell-mediated immunity. Rev Infect Dis 1984; 6: 814-831.
15. Brabin B. J. Epidemiology of infection in pregnancy. Rev Infect Dis 1985; 7: 579-603.
16. Blattner W., Gallo R. C., Temin H. M. HIV causes AIDS. Science 1988; 241: 515-516.
17. Fauci A. S. The human immunodeficiency virus: Infectivity and mechanisms of pathogenesis. Science 1988; 239: 617-622.
18. Smith R. D. The pathobiology of HIV infection. Arch Pathol Lab Med 1990; 114: 235-239.
19. Pantaleo G., Graziosi C., Fauci A. The immunopathogenesis of human immunodeficiency virus infection. N Engl J Med 1993; 328: 327-335.
20. Yerly S., Chamot E., Hirschel B., Perrin L. Quantitation of human immunodeficiency virus provirus and circulating virus: Relationships with immunologic parameters. J Infect Dis 1992, 166: 260-276.
21. Lafeuillade A., Tamalet C., Pellegrino P., DeMicco P., Vignoli C., Quilichini R. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection. J Acquir Immune Defic Syndr 1994; 7: 1028-1033.
22. Verhofstede C., Renier S., Van Wanzeele F., Plum J. Evaluation of proviral copy number and plasma RNA as early indicators of progression in HIV-1 infection: Correlation with virological and immunological markers of disease. AIDS 1994; 8: 1421-1427.
23. Galetto-Lacour A., Yerly S., Perneger T. V., Baumberger C., Hirschel B., Perrin L., The Swiss HIV cohort study. Prognostic value of viremia in patients with long-standing human immunodeficiency virus infection. J Infect Dis 1996; 173: 1388-1393.
24. Clerici M., Shearer G. M. The TH1-TH2 hypothesis of HIV infection: New insights. Immunol Today 1993; 15: 575-581.
25. Shearer G. M., Bernstein D. C., Tung K. S. K. et al. A model for the selective loss of major histocompatibility complex self restricted T cell immune responses during the development of AIDS. J Immunol 1986; 137: 2514-2521.
26. Creemers P. C., O'Shaughnessy M. V., Boyko W.J. Increased interleukin-2 receptor expression after mitogen stimulation on CD4- and CD8-positive lymphocytes and decreased interleukin-2 production in HLTV-III antibody-positive symptomatic individuals. Immunology 1986; 59: 627-629.
27. Prince H. E., Kleinman S., Williams A. E. Soluble IL-2 receptor in serum from blood donors seropositive for HIV. J Immunol 1988; 140: 1139-1141.
28. Simmonds P., Beatson D., Cuthbert R. J. G. et al. Determinants of HIV disease progression: Six-year longitudinal study in Edinburgh haemophilia/HIV cohort. Lancet 1991; 338: 1159-1163.
29. Lin R. Y., Nygren E., Valinsky J., Franklin M. Levels of soluble CD8 antigen and circulating immune complexes in intravenous drug abusers: Relationships to HIV antibody serology. AIDS Res Hum Retroviruses 1989; 5: 655-661.
30. Reddy M. M., Lange M., Grieco M. H. Elevated soluble CD8 levels in sera of human immunodeficiency virus-infected populations. J Clin Microbiol 1989; 27: 257-260.
31. Yagi M. J., Chu F. N., Jiang J. D. et al. Increases in soluble CD8 antigen in plasma, and CD8+ and CD8+CD38+ cells in human immunodeficiency virus type-1 infection. Clin Immunol Immunopathol 1992; 63: 126-134.
32. Fahey J. L., Taylor J. M. G., Detels R. et al. The prognostic value of cellular and serologic markers in infection with HIV-1. N Engl J Med 1990; 322: 166-172.
33. Osmond D. H., Shiboski S., Bacchetti P., Winger E. E., Moss A. R. Immune activation markers and AIDS prognosis. AIDS 1991; 5: 505-511.
34. Pedersen C., Nielsen C., Vestergaard B. F., Gerstoft J., Krogsgaard K., Nielsen J. O. Temporal relation of antigenemia and loss of antibodies to core antigen to development of clinical disease in HIV infection. Br Med J 1987; 295: 567-569.
35. Paul D. A., Falk L. A., Kessler H. A. Correlation of serum HIV antigen and antibody with clinical status in HIV-infected patients. J Med Virol 1987; 22: 357-363.
36. Aucouturier P., Couderc L. J., Gouet D. et al. Serum immunoglobulin G subclass dysbalances in the lymphadenopathy syndrome and acquired immune deficiency syndrome. Clin Exp Immunol 1986; 63: 234-240.
37. Lefrère J. J., Lambin P., Couroucé A. M., Doinel C. Progression to AIDS in the majority of asymptomatic HIV-infected people. AIDS 1989; 3: 603-604.
38. Schechter M. T., Craib K. J., Le T. N. et al. Progression to AIDS and predictors of AIDS in seroprevalent and seroincident cohorts of homosexual men. AIDS 1989; 3: 347-353.
39. Schwartlander B., Bek B., Skarabis B., Koch H., Burkowitz J., Koch M. A. Improvement of the predictive value of CD4+ lymphocyte count by β2-microglobulin, immunoglobulin A, and erythrocyte sedimentation rate. AIDS 1993; 7: 813-821.
40. Benenson A. S., ed. Control of Communicable Diseases Manual, 16th Edn. Washington, DC: American Public Health Association, 1995.
41. Strathdee S. A., O'Shaughnessy, Montaner J. S. G., Schechter M. T. Review: A decade of research on the natural history of HIV infection. 1. Markers. Clin Invest Med 1996; 19: 111-120.
42. Strathdee S. A., Hogg R. S., O'Shaughnessy, Montaner J. S. G., Schechter M. T. Review: A decade of research on the natural history of HIV infection. 2. Cofactors. Clin Invest Med 1996; 19: 121-130.
43. Süsal C., Daniel V., Opelz G. Does AIDS emerge from a disequilibrium between two complementary groups of molecules that mimic MHC? Immunol Today 1996; 17: 114-119.
44. Root-Bernstein R. S. Multiple-antigen-mediated autoimmunity (MAMA) in AIDS: A possible model for postinfectious autoimmune complications. Res Immunol 1990; 141: 321-339.
45. Bisset L. R. Molecular mimicry in the pathogenesis of AIDS: The HIV/MHC/mycoplasma triangle. AIDS 1995; 9: 243-251.
46. Zinkernagel R. M. Are HIV-specific CTL responses salutary or pathogenic? Curr Opin Immunol 1995; 7: 462-470.
47. Dalgleish A. G., Wilson S., Gompels M. et al. T-cell receptor variable gene products and early HIV-1 infection. Lancet 1992; 339: 824-828.
48. Westby M., Manca F., Dalgleish A. G. The role of host immune response in determining the outcome of HIV infection. Immunol Today 1996; 17: 120-126.
49. Root-Bernstein R. S., Hobbs S. H. Homologies between mycoplasma adhesion peptide, CD4, and class II MHC proteins: A possible mechanism for HIV-mycoplasma synergism in AIDS. Res Immunol 1991; 142: 519-523.
50. Hoff C., Peterson R. D. A. Minireview: Does exposure to HLA alloantigens trigger immunoregulatory mechanisms operative in both pregnancy and AIDS? Life Sci 1989; 45: iii-ix.
51. Hoff C., Peterson R. D. A. Lymphocyte alloantigenic challenge as a potential cofactor in HIV infection and progression to AIDS. Am J Hum Biol 1990; 2: 419-427.
52. Hoff C., James W. C., Hester R. B., Nolan P., Peterson R. D. A. Signs of cellular immunosuppression correlate with HLA-DR phenotypes in healthy, HIV-negative homosexuals: Preliminary findings. Hum Biol 1991; 129-135.
53. Golding H., Shearer G. M., Hillman K. et al. Common eitope in human immunodeficiency virus (HIV) I-gp41 and HLA class II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV 1-infected individuals. J Clin Invest 1989; 1430-1435.
54. Sheikh M. J., Ongrádi J., Austen B. M., Dalgleish A. G. The gp120 envelope of HIV-1 binds peptide in a similar manner to human leukocyte antigens. AIDS 1996; 9: 1229-1235.
55. Lo S. C., Tsai S., Benish J. R., Shih J. W., Wear D. J., Wong D. M. Enhancement of HIV-1 cytocidal effects in CD4+ lymphocytes by the AIDS-associated mycoplasma. Science 1991; 251: 1074-1076.
56. Wang R. Y. H., Shih J. W. K., Grandinetti T. et al. High frequency of antibodies to Mycoplasma penetrans in HIV-infected patients. Lancet 1992; 340: 1312-1316.
57. Montagnier L., Blanchard A. Mycoplasmas as cofactors in infection due to the human immunodeficiency virus. Clin Infect Dis 1993; 17: S309-315.
58. Blanchard A., Montagnier L. AIDS-associated mycoplasmas. Annu Rev Microbiol 1994; 48: 687-712.
59. Robinson W. E. Jr, Montefiori D. C., Mitchell W. M. Anti-body enhancement of human immunodeficiency virus type I infection. Lancet 1988; i: 790-795.
60. Robinson W. E., Kawamura T., Lake D., Masuho Y., Mitchell W. M., Hersh E. M. Antibodies to the primary immunodominant domain of human immunodeficiency virus type 1 (HIV-1) glycoprotein gp41 enhance HIV-1 infection in vitro. J Virol 1990; 64: 5301-5305.
61. Chowdhury M. I., Munakata T., Koyanagi Y., Arai S., Yamamoto N. Mycoplasma stimulates HIV-1 expression from acutely- and dormantly-infected promonocyte/monoblastoid cell lines. Arch Virol 1994; 139: 431-438.
62. Ter-Grigorov V. S., Krifuks O., Liubashevsky E., Nyska A., Trainin Z., Toder V. A new transmissible AIDS-like disease in mice induced by alloimmune stimuli. Nat Med 1997; 3: 37-41.
63. Burke D. S. Human HIV vaccine trials: Does antibody-dependent enhancement pose a genuine risk? Perspect Biol Med 1992; 35: 511-530.